BLEEDING PEPTIC ULCER – TERTIARY CENTER EXPERIENCE: EPIDEMIOLOGY, TREATMENT AND PROGNOSIS

Ivan Budimir¹, Sanja Stojsavljević¹, Davor Hrabar¹, Dominik Kralj¹, Alen Bišćanin¹, Lora Stanka Kirigin², Mario Zovak³, Žarko Babić⁴, Sven Bohnec⁵ and Ivan Budimir Jr⁶

¹Division of Gastroenterology, Department of Internal Medicine, Sestre milosrdnice University Hospital Center, School of Medicine and School of Dental Medicine, University of Zagreb, Zagreb, Croatia; ²Division of Endocrinology, Department of Internal Medicine, Sestre milosrdnice University Hospital Center, School of Medicine and School of Dental Medicine, University of Zagreb, Zagreb, Croatia; ³Department of Surgery, Sestre milosrdnice University Hospital Center, School of Medicine and School of Dental Medicine, University of Zagreb, Zagreb, Croatia; ⁴Division of Gastroenterology, Department of Internal Medicine, Dubrava University Hospital, Zagreb, Croatia; ⁵Gastroenterologie, Allgemeine Innere Medizin und Geriatrie, Rems-Murr Klinik Winnenden, Winnenden, Germany; ⁶Magdalena Department of Cardiovascular Diseases, Osijek School of Medicine, Krapinske Toplice, Croatia

SUMMARY – The aim of this study was to demonstrate epidemiological, clinical and endoscopic characteristics of acute upper gastrointestinal bleeding (UGIB) with special reference to peptic ulcer bleeding (PUB). The study included 2198 consecutive patients referred to our emergency department due to acute UGIB from January 2008 to December 2012. All patients underwent urgent upper GI endoscopy within 24 hours of admission, and 842 patients diagnosed with PUB were enrolled and prospectively followed-up. The cumulative incidence of UGIB was 126/100,000 in the 5-year period. Two out of five patients had a bleeding peptic ulcer; in total, 440 (52.3%) had bleeding gastric ulcer, 356 (42.3%) had bleeding duodenal ulcer, 17 (2%) had both bleeding gastric and duodenal ulcers, and 29 (3.5%) patients had bleeding ulcers on gastroenteric anastomoses. PUB was more common in men. The mean patient age was 65.9 years. The majority of patients (57%) with PUB were taking agents that attenuate the cytoprotective function of gastric and duodenal mucosa. Rebleeding occurred in 77 (9.7%) patients and 47 (5.9%) patients required surgical intervention. The 30-day mortality was 5.2% and 10% of patients died from uncontrolled bleeding and concomitant diseases. In conclusion, PUB is the main cause of UGIB, characterized by a significant rebleeding rate and mortality.

Key words: Gastrointestinal hemorrhage – epidemiology; Gastrointestinal hemorrhage – therapy; Peptic ulcer hemorrhage – epidemiology; Peptic ulcer hemorrhage – therapy; Endoscopy, gastrointestinal; Prognosis; Tertiary care centers; Croatia

Introduction

Upper gastrointestinal bleeding (UGIB) is a common medical emergency and accounts for 5% of emergency department presentations per year and 2% to 3% of hospital admissions in developed countries¹. The incidence rate of UGIB varies from 48 to 160 cases per 100,000 population, with consistent reports of higher

Correspondence to: Sanja Stojsavljević, MD, Division of Gastroenterology, Department of Internal Medicine, Sestre milosrdnice University Hospital Center, Vinogradska c. 29, HR-10000 Zagreb, Croatia
E-mail: sanja.stojsavljevic1@gmail.com
Received May 5, 2017, accepted June 7, 2017
incidence among men and the elderly. The most common cause of acute UGIB is non-variceal, where peptic ulcer bleeding (PUB) accounts for 28% to 59% of cases.

Endoscopy has become the standard of care in the diagnosis and treatment of UGIB. Most national and international guidelines recommend performing upper endoscopy within 24 hours of presentation in patients with UGIB. Despite major advances in diagnostic and therapeutic approaches, PUB remains a significant problem and an important cause of morbidity and mortality. Rebleeding after initial hemostasis occurs in 10% to 30% of patients with PUB. The reported PUB mortality rates in various countries across Europe range from 3.4% to 14%, and the reason for this difference remains unknown.

The aim of this prospective study was to determine the epidemiological, clinical and endoscopic characteristics of UGIB with a focus on the treatment and prognosis of PUB in a tertiary care center.

Patients and Methods

This prospective study was conducted in a tertiary care center in the City of Zagreb, Croatia, which covers a population of approximately 300,000 people. All consecutive patients presenting with UGIB (hematemesis, melena, hematochezia or blood admixture upon nasogastric aspiration) to the Emergency Internal Medicine Unit, Sestre milosrdnice University Hospital Center between January 2008 and December 2012 were included. These patients were then, if necessary, hospitalized in the Interventional Gastroenterology Unit of the same hospital. If the same patient was hospitalized more than once during the study period, only the first episode was counted as the incident case, irrespective of previous or subsequent episodes of PUB.

Upper gastrointestinal endoscopy was performed in all patients within 24 hours of hospital admission. Only patients with PUB confirmed by endoscopy were prospectively followed-up for 30 days. After initial endoscopic examination, patients in whom endoscopic therapy had been performed were hospitalized. All patients received high-dose acid suppression therapy (pantoprazole or esomeprazole 80 mg intravenously as an initial bolus followed by 40 mg intravenously and/or oral 3 times per day for at least 48 hours, followed by 40 mg daily per os).

Prior to endoscopy, a written informed consent was obtained from all patients or their relatives, which included possible risks, benefits and treatment options during the procedure. In addition, a written informed consent was obtained from patients or their relatives before trial entry. The study was approved by the Ethics Committee of the hospital. Data were collected prospectively into a database, with patient details stored in a depersonalized manner to protect patient confidentiality.

Data collection

The following data were collected for each patient: demographic data, signs and characteristics of the bleeding episode, symptoms and history of ulcer or liver disease, coexisting illness, drug use, laboratory results, endoscopic diagnosis including the cause of bleeding, presence of fresh blood/clots or stigmata of recent hemorrhage, endoscopic intervention, medical treatment, rebleeding incidence, surgical therapy, duration of hospitalization and cause of death. Shock was defined as syncope or signs of shock upon physical examination, including systolic blood pressure <100 mm Hg or heart rate >100 beats/min.

Grading of overall health and comorbidity was performed according to the American Society of Anesthesiology (ASA) classification (grade 1, normal healthy patients; grade 2, mild systemic illness; grade 3, severe, but incapacitating systemic illness; and grade 4, life-threatening illness). Stigmata of recent hemorrhage were defined according to Forrest classification as follows: Forrest Ia, spurting bleeding; Forrest Ib, oozing bleeding; Forrest IIa, non-bleeding visible vessel; Forrest IIb, adherent clot; Forrest IIc, hematin on ulcer base; and Forrest III, clean ulcer base. The size of ulcer was classified as <2 cm or ≥2 cm. The commonly used hemostatic procedures were epinephrine injections (1:10000 solution of epinephrine) and/or mechanical hemostasis with stainless steel hemoclips (Olympus, Japan) and/or thermocoagulation with a heater probe (Olympus, 7F, 20-30 joules).

Two biopsy specimens were obtained from the gastric antrum and body in all patients and the presence of Helicobacter pylori (H. pylori) infection was assessed by histopathologic examination of the specimens using hematoxylin-eosin (HE) stain. In all patients with gastric ulcers in whom recurrent bleeding was not observed, follow-up endoscopy was performed four to five days after initial hemostasis and biopsy specimens were ob-
tained from the margins and base of gastric ulcers to exclude malignancy. Follow-up endoscopy with histology was planned in all patients with gastric ulcers. In all patients with negative histology for *H. pylori* at index endoscopy, urea breath test (UBT) or follow-up endoscopy with histology was performed 2 weeks after proton pump inhibitor (PPI) treatment had been discontinued. Patients were considered positive for *H. pylori* infection in case of positive histology or positive UBT.

Clinical outcomes of PUB were analyzed according to the rebleeding rate, need for surgical intervention, need for blood transfusion, length of hospital stay, and 30-day mortality.

Rebleeding was defined as one or more signs of ongoing bleeding, including fresh hematemesis or melena, hematochezia, aspiration of fresh blood via nasogastric tube, instability of vital signs, and reduction of hemoglobin or hematocrit levels by more than 2 g/dL or 5%, respectively, over a 24-hour period after primary bleeding was stopped. Patients that had unsuccessful initial endoscopic treatment or more than two successful retreatments underwent emergency surgery.

**Statistics**

All analyses were performed with the Statistica 11.0 (Statsoft, Inc., Tulsa, OK) for Windows statistical package. The Mann-Whitney U-test and Kruskal-Wallis ANOVA test were used as nonparametric tests where appropriate, and a p-value <0.05 was considered significant. The predictive value of qualitative variables on mortality and rebleeding was studied in univariate analysis using Pearson χ²-test, when appropriate. Multivariate analysis was conducted using a forward elimination logistic regression model to identify a final set of variables independently associated with either mortality or rebleeding. A significance level α=0.05 was used to retain variables in the multivariate model. All results were presented as odds ratios (ORs) with the associated 95% confidence intervals (95% CIs).

**Results**

From January 2008 to December 2012, 2198 patients with UGIB were analyzed; 89.5% of patients had non-variceal bleeding, 8.3% had variceal bleeding, and in 2.2% the source was not identified.

In the group of patients with non-variceal bleeding, 42.8% had bleeding ulcer, while 57.2% had non-ulcer bleeding (Mallory-Weis tear, angiomata, Dieulafoy’s lesion, malignancy, acute erosive gastropathy, reflux esophagitis, portal hypertensive gastropathy, arterial enteric fistula). In patients with bleeding ulcers,
94.6% of cases were attributed to gastric or duodenal ulcers, 2% to both gastric and duodenal ulcers, and 3.4% to ulcer on previous gastroenteric anastomoses (Fig. 1).

The cumulative incidence of UGIB in the observed 5-year period was 126/100,000. In the group of 796 patients that were carefully followed-up, 55.3% had bleeding from gastric ulcers and 44.7% from duodenal ulcers. The mean patient age was 65.9 years and men had a higher incidence of bleeding (62.9% vs. 37.1%; p<0.001). High risk ulcers (Forrest Ia-IIb) were verified in 52% of patients, most ulcers were >2 cm in diameter, 9.7% of patients presented with shock, and 57.9% of patients had moderate to severe comorbidities. When analyzed according to medication usage, 28.3% of patients with peptic ulcers had been taking non-steroidal anti-inflammatory drugs (NSAIDs), 20.3% acetylsalicylic acid, 2.6% anti-aggregation medication, 5.8% anti-coagulation therapy, and 9.2% gastroprotective medication (histamine 2 blockers or PPI). *Helicobacter pylori* testing was performed in 531 (66.7%) patients of which 220 (41.4%) tested positive. The presence of *H. pylori* infection was more common in patients with duodenal peptic ulcer (46.7% vs. 36.9%), which was statistically significant (p<0.023) (Table 1).

Endoscopic treatment was performed in 456 (58.4%) patients; in 54.3% of cases hemostasis was achieved with hemoclips or with a combination of hemoclips and diluted epinephrine infiltration. Rebleeding occurred in 9.7% of patients (Table 2).

The risk of rebleeding was increased in patients with shock [OR 5.85 (CI 95% 3.01-11.37)], bleeding ulcer Forrest Ia type [OR 6.48 (CI 95% 3.12-13.48)] and ulcers >2 cm in diameter [OR 2.79 (CI 95% 1.49-5.20)] (Fig. 2).

Forty-seven (5.9%) patients were transferred to the Department of Surgery (5 due to successful endoscop-
ic hemostasis, 1 due to perforation during the procedure, and 41 due to recurrent bleeding). Most of the transferred patients had bleeding from the posterior wall of the duodenum, posterior proximal third of the gastric corpus, and from the small gastric curvature. The most common surgical procedure performed was mechanical hemostasis (ligation) and gastric resection. The total 30-day mortality was 5.2%. The risk of lethal outcome was increased in patients with shock [OR 2.74 (CI 95% 1.19–6.33)], recurrent bleeding [OR 3.54 (CI 95% 1.59–7.88)], ulcers >2 cm in diameter [OR 3.08 (CI 95% 1.50–6.33)] and moderate to severe comorbidities (ASA ≥3) [OR 6.32 (CI 95% 2.38–16.7)] (Fig. 3).

Discussion

There has been a significant decline in the incidence of PUB and its complications since the introduction of PPIs and H. pylori eradication therapy. A
lower incidence was observed in Sweden from 1987 to 2004 in both men and women, and one study conducted in the Netherlands found a decline from 61/100,000 to 48/100,000 per year from 1993 to 2000. In Germany and the United Kingdom, the incidence of PUB has remained unchanged, but the average patient age has increased. In the Zagreb County, Croatia, the incidence of UGIB and PUB did not significantly change from 2008 to 2012. This can be explained by the lower prevalence of *H. pylori* infection and increased use of drugs that affect the cytoprotective function of gastric mucosa (NSAIDs and acetylsalicylic acid), which has also been shown in other studies. The average patient age in this study was higher than 65 years. In one study, Van Leerdam found that 70% of patients with UGIB were older than 60 years and 40% had several life-threatening diseases, and in another one Van Leerdam et al. report that about 50% of patients with PUB were taking NSAIDs and acetylsalicylic acid, with only 12% of them taking PPI as protection. *H. pylori* infection was diagnosed in 40% of patients and was found more frequently in patients with bleeding duodenal ulcers. In one prospective study conducted in the Netherlands, *H. pylori* testing was performed in 65% of patients with 43% having positive findings, while a German study found that 56% of patients with PUB were *H. pylori* positive. Gralnek et al. found that PUB made up 28% to 59% of all UGIB. Half of the patients were categorized as high-risk ulcer patients (Forrest Ia, Ib, IIa and IIb). In a study by Bratanic et al., around 30% of patients were described as high-risk. In our study, PUB represented about 40% of all non-variceal UGIB, and bleeding gastric ulcers were found more frequently than bleeding duodenal ulcers. Rebleeding after endoscopic treatment with endoclips or endoclips/diluted epinephrine occurred in 10% of patients and 5.9% of them required surgical intervention. The risk of recurrent bleeding was increased in patients with shock, actively bleeding ulcers, and ulcers larger than 2 cm in diameter. Our results are consistent with the results from other tertiary centers, and despite all endoscopic methods for hemostasis available, acute recurrent hemorrhage is still common, occurring in 10% to 28% of cases. We report a total 30-day mortality of 5.2%. Only 10% of patients died because of bleeding out, while others died from other comorbidities. Mortality was increased in patients with shock, recurrent bleeding ulcers larger than 2 cm in diameter, and moderate to severe comorbidities (ASA ≥3). Almost 60% of patients with PUB presented with moderate to severe comorbidities (ASA III and IV). When considering other studies, Marmo et al. report a PUB mortality rate of 4% to 5% in one prospective study. Van Leerdam et al. showed that 40% of patients that died because of UGIB had one or several life-threatening comorbidities. Marmo et al. showed that in the first 24 hours of hospitalization, less than 30% of all patients died. Villauneva et al. compared the efficacy of a restrictive transfusion strategy (target hemoglobin 7-9 g/dL) with that of a liberal transfusion strategy (target hemoglobin 9-11 g/dL) in patients with acute gastrointestinal bleeding, finding that the probability of survival at 6 weeks was higher in the restrictive-strategy group. This was also observed in a subgroup analysis of patients with PUB. Other authors also suggest better patient outcomes when the restrictive red blood cell transfusion strategy is used. In our study, half of the patients received red blood cell transfusions, with a median of 2.2 units.

The limitations of this study included diverse medical staff involved in endoscopic evaluation and treatment, resulting in inter-observer variability in endoscopic evaluation and treatment. Furthermore, this study had a short follow-up period of 30 days and was conducted in a tertiary center.

In conclusion, the incidence of UGIB and PUB remained unchanged in the observed period from 2008 to 2012, but we recorded an increase in the average age of PUB patients. Predictors of mortality in patients with PUB included shock, recurrent bleeding, ulcers larger than 2 cm in diameter, and moderate to severe comorbidities. Prevention of PUB, prompt intravascular volume replacement, early (≤24 hours) upper GI endoscopy, and a restrictive red blood cell transfusion strategy are important in the management of these patients.

References

Acta Clin Croat, Vol. 56, No. 4, 2017 713


Sažetak

KRVARENJE IZ PEPTIČKOG VRIJEDA – ISKUSTVA TERCIJARNOG CENTRA: EPIDEMIOLOGIJA, LIJEČENJE I PROGNOZA

I. Budimir, S. Stojancević, D. Hrabar, D. Kralj, A. Bišćanin, L.S. Kirigin,
M. Zovak, Ž. Babić, S. Bohnec i I. Budimir ml.

Cilj ove studije bio je prikazati epidemiološke, kliničke i endoskopske karakteristike akutnog krvarjenja iz gornjeg probavnog sustava s naglaskom na krvarjenje iz peptičkog vrijeda. U studiju je bilo uključeno 2198 bolesnika koji su pregledani u hitnoj službi naše ustanove zbog akutnog krvarjenja iz gornjeg probavnog sustava u razdoblju od siječnja 2009. do prosinca 2012. godine. Svim bolesnicima je učinjena hitna gastroskopija unutar 24 sata od prijma, a u 842 bolesnika kod kojih je dokazana peptička ulkusna bolest nastavljeno je kliničko praćenje. Kumulativna incidencija krvarjenja je bila 126/100.000 u razdoblju od 5 godina. Dva od pet bolesnika su imali krvarući peptički vrijed; ukupno 440 (52,3%) bolesnika je imalo krvareći želučani vrijed, 356 (42,3%) duodenalni vrijed, 17 (2%) želučani i duodenalni vrijed, a 29 (3,5%) krvareći vrijed na gastroenteralnoj anastomozi. Srednja dob bolesnika je bila 65,9 godina. Većina bolesnika je uzimala lijekove koji suprimiraju citoprotektivne funkcije želučane i duodenalne služnice (57%). Recidiv krvarjenja zabilježen je u 77 (9,7%) bolesnika, a 47 (5,9%) je zahtijevalo kiruršku intervenciju. Smrtnost kroz 30 dana je bila 5,2%, a 10% bolesnika je umrlo zbog krvarjenja i pratećih komorbiditeta. Krvarjenje iz peptičkog vrijeda je najčešći uzrok krvarjenja iz gornjeg probavnog sustava, a obilježeno je značajnom stopom recidiva krvarjenja i smrtnosti.

 Ključne riječi: Gastrointestinalno krvarjenje – epidemiologija; Gastrointestinalno krvarjenje – terapija; Peptički vrijed, krvarjenje – epidemiologija; Peptički vrijed – terapija; Endoskopija, gastrointestinalna; Prognoza; Tercijarni zdravstveni centri; Hrvatska